NEWS & EVENTS

Latest news and upcoming events

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases
14 Sep 2022

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

Upcoming events
  • Women in venture Capital Summit:Europe
    26 – 27 September 2022,
    Paris

    download
  • Brain Innovation Days
    11 – 12 October 2022,
    Brussels

    download
  • BIO-EUROPE 2022
    24 - 26 October 2022,
    Leipzig

    download

TiGenix Business and Financial Update for the First Half of 2014

Leuven, Belgium – 26 August, 2014 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, issued an update on business and financial progress in the first half of this year today.

European Medicines Agency renews Marketing Authorisation for ChondroCelect

Leuven (BELGIUM) – 1 July, 2014 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that the Committee for Medicinal Products for Human Use (CHMP) has renewed for an additional five years its marketing authorisation for ChondroCelect in all of the 31 countries of the European Union (EU) and European Economic Area (EEA).

TiGenix announces the clinical development of Cx611 in early rheumatoid arthritis and severe sepsis

Leuven, Belgium – 30 June, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it will develop its intravenous-administered allogeneic stem cell product, Cx611, for patients suffering from early rheumatoid arthritis and for patients suffering from severe sepsis, a potentially life-threatening complication of infection.

Kala Pharmaceuticals Initiates Phase 3 Clinical Trial for Treatment of Post-­Surgical Ocular Inflammation and Phase 2 Clinical Trial in Dry Eye Disease

WALTHAM, Mass.,June 19, 2014--Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform, today announced the initiation of two clinical trials with its nanotechnology-based loteprednol etabonate MPP (LE-MPP) program, KPI-121.

CVRx® Achieves Two Significant Milestones for its Heart Failure and Hypertension Businesses

Minneapolis – June 9, 2014 – CVRx, Inc., a private medical device company, announced today it achieved two significant milestones in its heart failure and hypertension businesses.

TiGenix completes the sale of its Dutch manufacturing facility to PharmaCell

Leuven, Belgium – 2 June, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it has completed the sale of its Dutch production facility to PharmaCell BV for a total consideration of Euro 5.75 million.

TiGenix Business and Financial Update for the first quarter of 2014

Leuven, Belgium - 13 May, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, issued today a business and financial update for the first three months of 2014.

St. Jude Medical Announces TOCCASTAR Clinical Trial Meets Primary Safety and Efficacy Endpoints at Heart Rhythm 2014

ST. PAUL, Minn.--(BUSINESS WIRE)-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results of the TOCCASTAR clinical trial at Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions in San Francisco.

Kala Pharmaceuticals Announces $22.5 Million Series B Financing

Waltham, Mass., April 23, 2014 – Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has completed a $22.5 million Series B financing.

TiGenix licenses exclusive marketing and distribution rights for ChondroCelect to Sobi

Leuven (BELGIUM) – April 3, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it has licensed the marketing and distribution of ChondroCelect, the cell-based medicinal product for the repair of cartilage defects of the knee, to the international specialty healthcare company dedicated to rare diseases, Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI).

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.